It works through several mechanisms: Appetite regulation : Semaglutide acts on receptors in the brain's appetite centres, particularly the hypothalamus, reducing hunger and increasing satiety after meals Delayed gastric emptying : It slows the rate at which food leaves the stomach, prolonging feelings of fullness (this effect may be most pronounced during dose escalation) Glucose-dependent insulin secretion : In the presence of elevated blood glucose, it stimulates pancreatic beta cells to release insulin Glucagon suppression : It reduces inappropriate glucagon secretion from pancreatic alpha cells, thereby limiting hepatic glucose production These combined effects result in significant weight lossaround 15% of body weight in people without diabetes and approximately 9-10% in people with type 2 diabetes, according to clinical trialsand improved glycaemic control in people with type 2 diabetes
tablets)
Research-grade quality standards
Semaglutide, liraglutide, and tirzepatide are injectable GLP-1RA drugs that act as GLP-1 receptor agonists [6,7,8,9]
By Route of Administration, Injectables Remain the Backbone Through 2035 Injectable formulations account for nearly 99% of obesity GLP-1 therapy use in 2025, reflecting their status as the established delivery route for both semaglutide and tirzepatide
What other services are you interested in learning about